Carole Faig.
Henry Schein’s board of directors has appointed Carole Faig as an independent director to serve until the 2024 annual meeting of stockholders in May, when she is expected to be reelected.
Faig has experience in finance, audit, and public accounting, specifically in the healthcare industry. She spent 38 years at Ernst & Young before retiring in July 2021. Currently, Faig is a board member at Cue Health, Affinia Therapeutics, and QuVa Pharma.
